» Articles » PMID: 37353338

Exacerbations of COPD

Overview
Journal Respir Care
Publisher Mary Ann Liebert
Specialty Pulmonary Medicine
Date 2023 Jun 23
PMID 37353338
Authors
Affiliations
Soon will be listed here.
Abstract

COPD exacerbations are associated with significant morbidity, mortality, and increased health care expenditures. The recently published Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations have further refined the definition of an exacerbation. A better understanding of the risk factors associated with the development of an exacerbation exists, and improvements are being made in earlier detection approaches. Pharmacologic treatment strategies have been the cornerstone of effective therapy. In addition, both pharmacologic and non-pharmacologic strategies have been proven successful in the prevention of future exacerbations. Newer technologies, including the use of artificial intelligence and wearable monitoring devices, are now being used to help in the earlier detection of exacerbations. Such preventive and earlier detection strategies can help to develop a more personalized care model and improve outcomes for patients with COPD.

Citing Articles

Early Identification of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD).

Voulgareli I, Antonogiannaki E, Bartziokas K, Zaneli S, Bakakos P, Loukides S J Clin Med. 2025; 14(2).

PMID: 39860403 PMC: 11765565. DOI: 10.3390/jcm14020397.

References
1.
Singh D, Edwards L, Tal-Singer R, Rennard S . Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010; 11:77. PMC: 2904285. DOI: 10.1186/1465-9921-11-77. View

2.
Albert R, Connett J, Bailey W, Casaburi R, Cooper Jr J, Criner G . Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365(8):689-98. PMC: 3220999. DOI: 10.1056/NEJMoa1104623. View

3.
Cox N, Oliveira C, Lahham A, Holland A . Pulmonary rehabilitation referral and participation are commonly influenced by environment, knowledge, and beliefs about consequences: a systematic review using the Theoretical Domains Framework. J Physiother. 2017; 63(2):84-93. DOI: 10.1016/j.jphys.2017.02.002. View

4.
Poole P, Chong J, Cates C . Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015; (7):CD001287. DOI: 10.1002/14651858.CD001287.pub5. View

5.
Cecere L, Slatore C, Uman J, Evans L, Udris E, Bryson C . Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). COPD. 2012; 9(3):251-8. DOI: 10.3109/15412555.2011.650241. View